Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
ARRONAX is a high-energy cyclotron facility based in Nantes, France, operating as a Public Interest Group (GIP). It specializes in the production of innovative radioisotopes for nuclear medicine, particularly for targeted alpha therapy and PET imaging. The facility operates a unique IBA C70 cyclotron capable of accelerating various particles to high energies, supporting international research in radiochemistry, oncology, and nuclear physics. ARRONAX serves as a critical supplier and contract manufacturer for medical isotopes such as Astatine-211, Strontium-82, and Copper-64. Through its interdisciplinary approach, the organization facilitates the development of new radiopharmaceuticals from basic research to clinical application.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Cyclotron ARRONAX.